Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 9/2010

Content (15 Articles)

Open Access Review

Anti-HER2 vaccines: new prospects for breast cancer therapy

Maha Zohra Ladjemi, William Jacot, Thierry Chardès, André Pèlegrin, Isabelle Navarro-Teulon

Original Article

Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy

Minh C. Nguyen, Guang Huan Tu, Kathryn E. Koprivnikar, Melissa Gonzalez-Edick, Karin U. Jooss, Thomas C. Harding

Original Article

IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy

Mike W. Helms, Jennifer A. Prescher, Yu-An Cao, Steven Schaffert, Christopher H. Contag

Original Article

Bioactivity and pharmacokinetics of two human serum albumin–thymosin α1-fusion proteins, rHSA-Tα1 and rHSA-L-Tα1, expressed in recombinant Pichia pastoris

Jian-Hua Chen, Xin-Guo Zhang, Yu-tao Jiang, Lu-Ying Yan, Li Tang, Yi-Wei Yin, Dai-Shuang Cheng, Jing Chen, Min Wang

Original Article

Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice

Flávia Gomes de Góes Rocha, Karen Cristina Barbosa Chaves, Roger Chammas, Jean Pierre Schatzmann Peron, Luiz Vicente Rizzo, Nestor Schor, Maria Helena Bellini

Original Article

Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy

David Coe, Shaima Begom, Caroline Addey, Matthew White, Julian Dyson, Jian-Guo Chai

Open Access Original Article

Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells

Antje Hoff, Ana-Cristina Bagû, Thomas André, Günter Roth, Karl-Heinz Wiesmüller, Brigitte Gückel, Roland Brock

Original Article

Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer

A. Heller, I. Zörnig, T. Müller, K. Giorgadze, C. Frei, T. Giese, F. Bergmann, J. Schmidt, J. Werner, M. W. Buchler, D. Jaeger, N. A. Giese

Original Article

Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners

Xinmei Zhu, Beth A. Fallert-Junecko, Mitsugu Fujita, Ryo Ueda, Gary Kohanbash, Edward R. Kastenhuber, Heather A. McDonald, Yan Liu, Pawel Kalinski, Todd A. Reinhart, Andres M. Salazar, Hideho Okada

Short communication

Phenotypic characterization of chronic inflammation in a rare case of endobronchial carcinoma

Philippe O. Gannon, Simon Turcotte, Jean-Luc Laporte, Fred Saad, Réjean Lapointe, André Duranceau

Meeting Report

CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer

Mustafa Diken, Melanie Widenmeyer, Cécile Gouttefangeas, Marij J. P. Welters, Cedrik M. Britten

Open Access Focussed Research Review

MHC-based detection of antigen-specific CD8+ T cell responses

Sine Reker Hadrup, Ton N. Schumacher

Open Access Focussed Research Review

Modeling flow cytometry data for cancer vaccine immune monitoring

Jacob Frelinger, Janet Ottinger, Cécile Gouttefangeas, Cliburn Chan

Focussed Research Review

New strategies for the manipulation of adaptive immune responses

Tobias Bopp, Markus Radsak, Edgar Schmitt, Hansjörg Schild

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine